SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust ($SLV) is experiencing intense bullish momentum, driven by spot silver prices reaching new all-time highs. This rally is fueled by tightening global supply due to upcoming Chinese export restrictions, alongside booming industrial demand from EV batteries, solar, and AI data centers. The community is actively discussing a potential 'silver squeeze' and a significant re-rating of silver's value, though some anticipate a near-term pullback after its rapid ascent.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors celebrate the recent FDA approval of YARTEMLEA, the first and only treatment for a life-threatening post-transplant complication, sparking a fervent discussion on its potential. The community believes the stock is significantly undervalued, pointing to a strategic partnership with Novo Nordisk and a strong pipeline, fueling speculation of a massive short squeeze and potential buyout. Anticipation is high for further details on commercialization plans and pricing, with many urging long-term holds.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending amidst significant network upgrades, including the rollout of Polkadot 2.0 featuring elastic scaling, a new supply cap for DOT with halving emissions, and a migration of governance and staking to its Asset Hub chain. Community sentiment is notably divided, with proponents viewing these tokenomic shifts as strong bullish catalysts for long-term growth and others expressing deep skepticism regarding past performance and future prospects. These developments also unfold alongside discussions of its interoperability within the broader crypto ecosystem and ongoing dialogues around potential crypto ETF approvals.

abrdn ETF - abrdn Physical Platinum Shares ETF

abrdn Physical Platinum Shares ETF (PPLT) is experiencing a notable surge in trading volume and price, fueled by strong community sentiment anticipating a significant breakout. Discussions highlight platinum's projected supply deficits, rising industrial demand for automotive catalysts and green energy, and its perceived undervaluation relative to gold. This bullish outlook is further intensified by geopolitical risks affecting key mining regions.

Enbridge, Inc. engages in the provision of gas and oil. It operates through the following segments: Liquid Pipelines, Gas Distribution and Storage, Gas Transmission and Midstream, Renewable Power Generation, and Energy Services. The Liquids Pipelines segment consists of common carrier and contract crude oil, natural gas liquids and refined products pipelines and terminals in Canada and the U.S., including Canadian Mainline, Regional Oil Sands System, Southern Lights Pipeline, Spearhead Pipeline, Seaway Crude Pipeline interest, and other feeder pipelines. The Gas Distribution & Storage segment consists of natural gas utility operations, the core of which is Enbridge gas, which serves residential, commercial and industrial customers. It also includes natural gas distribution activities in Quebec and an investment in Noverco, which holds a majority interest in a subsidiary entity engaged in distribution and energy transportation primarily in Quebec. The Gas Transmission & Midstream segment consists of investments in natural gas pipelines, processing and green energy projects, the company's commodity marketing businesses, and international activities. The Renewable Power Generation segment consists primarily of investments in wind and solar power generating assets, as well as geothermal, waste heat recovery, and transmission assets. The Energy Services segment consists of businesses in Canada and the United States including logistical services, refinery supply services and the firm's volume commitments on various pipeline systems. The company was founded on April 30, 1949 and is headquartered in Calgary, Canada.

Enbridge Inc

Enbridge is trending amid recent positive legal and regulatory developments concerning its critical pipeline infrastructure, which is easing political uncertainties. The community is focused on the company's consistent dividend growth and strategic initiatives, including major acquisitions and new ventures designed to capitalize on increasing natural gas demand from data centers and LNG exports. Investors are evaluating Enbridge's long-term stability and growth prospects within the evolving energy landscape.

abrdn ETF - abrdn Physical Silver Shares ETF

SIVR is trending as silver surges to fresh multi-year highs, captivating community discussions with widespread optimism for continued gains. This rally is primarily fueled by robust safe-haven demand, expectations of looser monetary policy, and tightening supply amidst growing industrial use. Many investors are actively discussing silver's potential for further upside, especially given its historical performance relative to gold and broader macroeconomic uncertainties.

Direxion Shares ETF Trust - Direxion Daily S&P 500 Bull 3X Shares

Direxion Daily S&P 500 Bull 3X Shares

Direxion Daily S&P 500 Bull 3X Shares is trending as the broader S&P 500 index recently achieved new record highs, fueling fervent bullish sentiment. The community is actively debating whether this marks the continuation of an upward rally, prompting many to buy dips and leverage for amplified gains. While economic indicators and discussions around central bank policies add context, traders are keenly focused on riding the market's momentum.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is a major talking point in the drone sector, propelled by the FCC's recent ban on foreign-made drones and the passage of the NDAA, both signaling increased opportunities for US manufacturers. The community is actively debating the potential for significant defense contracts, especially for its Black Widow platform and emerging unmanned surface vessels, though some express skepticism about revenue timelines and management's communication given previous expectations.

Ecolab, Inc. engages in providing products and services in the field of water, hygiene, and energy. It operates through the following segments: Global Industrial, Global Institutional and Specialty, Global Healthcare and Life Sciences, Global Pest Elimination, and Corporate. The Global Industrial segment relates to water, food and beverage, paper, and downstream operating segments. The Global Institutional and Specialty segment refers to the institutional, specialty, and healthcare operating segments. The Global Healthcare and Life Sciences segment includes the healthcare and life sciences operations. The Global Pest Elimination segment provides services designed to detect, prevent and eliminate pests, such as rodents and insects, in full-service and quick-service restaurants, food and beverage processors, hotels, grocery operations, and other. The company was founded by Merritt J. Osborn in 1923 and is headquartered in St. Paul, MN.

Ecolab, Inc.

Ecolab is trending as it strategically expands into high-tech water solutions for the semiconductor and AI data center sectors, launching new cooling technologies. This move, coupled with recent analyst upgrades and strong earnings performance, has the community actively discussing its potential as a reliable long-term growth story focused on innovation and sustainability.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) is currently trending as investors eagerly anticipate upcoming monthly dividend payouts, often citing them as a reliable source of income. The community actively debates JEPQ's performance and tax efficiency against similar covered-call ETFs, with many viewing recent price dips as attractive buying opportunities for long-term retirement portfolios. Its strategy of generating income from Nasdaq-listed equities continues to appeal to those seeking steady distributions amid broader market fluctuations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of CNS Pharmaceuticals, Inc. (CNSP) declined 5% on Friday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://cnspharma.com/ir/press-releases/cns-pharmaceuticals-announces-primary-analysis-of-berubicin-in-second-line-treatment-of-glioblastoma-multiforme-44471506">reported </a>wider losses in the first quarter (Q1).The firm’s net loss for the three months ended March 31, 2025, was approximately $4.3 million, compared to approximately $3.5 million for the comparable period in 2024.The company said the increase in net loss is largely attributable to the costs of data clean-up, preparation, and analysis for the topline primary data release on the Berubicin trial in brain cancer.CNS Pharmaceuticals’ research and development expenses rose to $3.2 million in the quarter, while general and administrative expenses fell marginally to $1.09 million, owing to a decrease in stock-based compensation, marketing, advertising, and insurance expenses.The company ended the quarter with cash of approximately $13.1 million. CNS believes that the cash on hand as of March 31, 2025, in addition to the $5 million raised from a public offering earlier this month, is sufficient to fund planned operations into the second half of 2026.CNS is developing treatments for cancers in the brain and central nervous system. By year-end, the company intends to commence the phase 2 study of its lead program, TPI 287, for treating Glioblastoma Multiforme (GBM). Glioblastoma multiforme (GBM) is the most common form of cancer that originates in the brain.On Stocktwits, retail sentiment around CNSP remained ‘extremely bullish’ over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_16_at_9_01_42_AM_png_cf9bcf9c43.webp" alt="CNSP's Sentiment Meter and Message Volume as of 9 a.m. ET on May 16, 2025 | Source: Stocktwits" width="627" height="63"><figcaption>CNSP's Sentiment Meter and Message Volume as of 9 a.m. ET on May 16, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CNSP">CNSP stock</a> is down by 80% this year and over 99% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-ceo-to-step-down/chiw5m5Rbno">Novo Nordisk CEO Lars Jørgensen Steps Down Amid Challenges, Retail Chatter Spikes</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved

The company intends to commence the phase 2 study of its lead program, TPI 287, to treat Glioblastoma Multiforme (GBM) by year-end.

Equity

This account has been verified as an official CNSP representative.

Verified Account

CNS Pharma

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Current Price	$6.20
Prev Close	$6.23
Open	$6.15
Dividend Yield	0.00%
50-Day Moving Average	$7.25
Beta	0.98
Avg. Volume	14,412.53
PE Ratio	-0.11

52-Week High	$114.00
52-Week Low	$4.93
Market Capitalization	$3.85M
EPS (Annual)	-$466.44
Price to Book	0.36
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

CNSP
Cns Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CNSP News

CNSPCns Pharmaceuticals Inc